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Upper-body morbidity following breast cancer
treatment is common, may persist longer-term
and adversely influences quality of life
Sandra C Hayes1,2*, Sheree Rye1,2, Diana Battistutta2, Tracey DiSipio1,2, Beth Newman1,2
Abstract
Background: Impairments in upper-body function (UBF) are common following breast cancer. However, the
relationship between arm morbidity and quality of life (QoL) remains unclear. This investigation uses longitudinal
data to describe UBF in a population-based sample of women with breast cancer and examines its relationship
with QoL.
Methods: Australian women (n = 287) with unilateral breast cancer were assessed at three-monthly intervals, from
six- to 18-months post-surgery (PS). Strength, endurance and flexibility were used to assess objective UBF, while
the Disability of the Arm, Shoulder and Hand questionnaire and the Functional Assessment of Cancer Therapy-
Breast questionnaire were used to assess self-reported UBF and QoL, respectively.
Results: Although mean UBF improved over time, up to 41% of women revealed declines in UBF between six-
and 18-months PS. Older age, lower socioeconomic position, treatment on the dominant side, mastectomy, more
extensive lymph node removal and having lymphoedema each increased odds of declines in UBF by at least two-
fold (p < 0.05). Lower baseline and declines in perceived UBF between six- and 18-months PS were each
associated with poorer QoL at 18-months PS (p < 0.05).
Conclusions: Significant upper-body morbidity is experienced by many following breast cancer treatment,
persisting longer term, and adversely influencing the QoL of breast cancer survivors.
Background
Whether as a consequence of earlier detection methods
and/or advances in treatment, survival following breast
cancer is among the best of any cancer [1]. Good survi-
val prospects contribute to the significant and growing
number of breast cancer survivors, making quality of
survival an important personal and public health issue
warranting research attention.
Work published more than a decade ago highlighted
that between 15-45% of breast cancer survivors reported
impairments in upper-body function (UBF) up to one
year post-surgery, depending on timing of assessment
and the particular impairment [2-4]. While impaired
arm function was short-lived for some, a subgroup of
women reported persisting problems longer term [5].
Since this work, the majority of published literature
describing UBF following breast cancer compares out-
comes of treatment techniques (e.g., sentinel node
biopsy versus axillary dissection; breast-conserving sur-
gery versus mastectomy; radiation to the chest wall and
axilla versus to the axilla only) [6-11]. The studies tend
to be retrospective and are subject to the greater poten-
tial for selection bias associated with clinic- rather than
population-based samples [12-14]. Further, the literature
relies on self-reported measures of UBF, typically in the
absence of clinical assessment. These design limitations
are critical: lack of longitudinal data compromises gen-
eralisability of study results; focus on treatment out-
comes has overshadowed the potential impact of other
personal and/or behavioural characteristics; and previous
work has demonstrated that correlations between objec-
tive and self-reported measures of UBF are only modest
(r = -0.2-0.3) indicating they reflect different constructs,
with both the direction and magnitude of relationships
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with other characteristics varying depending on how
UBF is measured [15]. For example, those treated on
the dominant side show better UBF when assessed clini-
cally, but report poorer perceived function, when com-
pared with those treated on their non-dominant side.
A systematic review, published in 2003 [16], was under-
taken to describe the relationship between upper-body
morbidity and quality of life (QoL). The authors concluded
that while arm morbidity was associated with poorer QoL,
the strength of the association was considered low and
only four investigations contributed to their findings.
Since the review, others have demonstrated that upper-
body impairments adversely affect the ability to participate
in daily activities as well as QoL [17-19], and there is evi-
dence to suggest QoL predicts survival [20]. However, the
study designs of this research have limited the evaluation
of a causal pathway between UBF and QoL.
This investigation prospectively describes UBF, mea-
sured objectively and self-reported, in a population-based
sample of women with breast cancer between six- and 18-
months post-surgery (PS). The characteristics associated
with UBF and its relationships with QoL are examined.
Methods
Patient group
This work forms a planned component of a broader
study, The Pulling Through Study, which was designed
to document the prevalence and severity of problems,
including UBF, between six- and 18-months following
breast cancer surgery among Australian women [21].
Women aged 74 years or younger, with a first diagnosis
of invasive, unilateral breast cancer, and residing within
a 100 kilometre radius of Brisbane, Queensland, were
eligible for participation. Eligibility criteria minimised
the impact of age-related co-morbidities on study find-
ings, allowed for the untreated side to serve as a ‘con-
trol’ for certain outcomes, and enabled attendance at
regular clinical assessments. Younger women (< 50
years) were over-sampled to ensure adequate numbers
were available for specific age group analyses. Popula-
tion-based sampling was undertaken through the
Queensland Cancer Registry. It takes three to four
months from the point of cancer diagnosis for patient
information to arrive at the registry. Consequently,
recruitment procedures commenced around four
months PS. Following ethical approval (Queensland Uni-
versity of Technology, Ref No 2179H), doctor consent
was obtained for 417 women (82% of random sample).
Participant consent was obtained from 71% (n = 294);
thereafter, seven women decided not to participate or
could not be recontacted. Hence, 287 women partici-
pated in baseline measures; the majority participated in
all components of data collection (75%), while the
remainder participated on a ‘questionnaire-only’ basis.
Data collection
Clinical assessment of UBF and completion of patient-
administered questionnaires occurred every three
months, over a 12-month period, with baseline assess-
ment at six-months PS. Disease characteristics were col-
lected from pathology reports at the Queensland Cancer
Registry. Personal characteristics (such as side of domi-
nance and income) were self-reported, and lymphoe-
dema status was evaluated objectively using
bioimpedance spectroscopy [21].
Objective upper-body function
Clinical assessments of UBF were conducted for strength
and endurance, hand grip strength, and flexibility, in that
order. Upper-body strength and endurance (UBSE) were
measured using an incremental exercise protocol, with
each stage lasting one minute in duration and increments
made by increasing speed of movement and weight held
(0.5 kilogram increments, with the first one-minute stage
commencing with no weight held). The movement com-
bined a traditional ‘upright row’ and ‘shoulder press’, but
the specific range of movement was individualised for
each participant and each arm. To advance levels, the
participant must have maintained correct form, range of
movement and speed for the entire one-minute stage.
Weight (kilograms, kg) held during the last successfully
completed stage, assessed separately for each arm, was
recorded. More details including comparison of this tech-
nique with assessment of strength and endurance using
an isokinetic dynamometer are reported elsewhere [15].
A standard calibrated hand dynamometer (TTM Original
Dynamometer 100 kg, Tokyo) was used to measure iso-
metric hand grip strength (HGS). Three maximal con-
tractions on each side, alternating between sides to allow
for rest between each contraction, were performed and
the maximum score achieved for each hand was
recorded. Goniometry of flexion of the shoulder was
used as a measure of shoulder flexibility. The participant
was asked to hold her arm by her side, palm of hand
positioned medially. The testing arm was then moved
upward in the sagittal plane (in the flexion direction), as
far as possible, with the palm of the hand always facing
medially and elbow joint extended at 180 degrees. The
test was undertaken twice for each side, alternating
between sides. A third measure was taken when the first
two measures differed by more than five degrees. The
maximum range achieved for each arm was recorded. For
all objective measures, results from the treated side are
presented here.
Subjective upper-body function
The Disability of the Arm, Shoulder and Hand (DASH)
questionnaire was used to assess self-reported UBF. The
DASH [22] comprises 30 items and collects information
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about the level of difficulty experienced when performing
specific tasks, the extent to which any upper-body pro-
blem interferes with normal activities, and the severity of
specific upper-body symptoms. Final scores range from 0
to 100, where 0 reflects no disability (good function) and
100 reflects extensive disability (poor function).
Quality of life
The Functional Assessment of Cancer Therapy-Breast
(FACT-B+4) questionnaire was included in the self-
administered survey, to provide a measure of QoL. Final
scores range from 0 to 160 whereby 0 reflects low QoL
and 160 reflects high QoL. This QoL tool has been
widely used and extensively described, including its
validity and reliability, by others [23].
Statistical Analysis
Distributions of UBF and QoL measures were approxi-
mately Normally distributed, hence means and standard
deviations (SD) were used to summarise data at each
phase. Absolute change in UBF between six- and 18-
months PS was calculated and used to categorise partici-
pants as experiencing declines, no change, or improve-
ments in UBF over time. Clinically, we argue that
improvement following surgery is expected, with any
decline in function over time potentially important,
although we acknowledge that measurement error may
account for some misclassification of decliners. In a sen-
sitivity analysis of this strict position, we also categorised
decline according to changes of more than 10% and rea-
nalysed. Binary logistic regression was used to explore
characteristics associated with declines in function,
while regression models utilising a general linear model-
ling framework were used to investigate predictive rela-
tionships between function and QoL. Final regression
models presented include adjustment for all potential
confounders identified by statistical and/or clinical sig-
nificance (further details regarding modelling provided
in Hayes et al [21]). Differences of seven units in the
FACTB+4 total score [23] and odds ratios (OR) of > 2
or < 0.5 were considered a priori as potentially clinically
important, while a two-tailed p < 0.05 was considered
statistically significant. Means (95% confidence interval,
CI) and odds ratios (95% CI) are presented for continu-
ous and dichotomous outcomes, respectively. Underlying
assumptions for these analytical techniques, including
the absence of multi-collinearity, were tested and met.
Results
Study participants had similar demographic and clinical
characteristics compared with the parent sample (n =
511), as presented elsewhere [21]. In summary, average
age of participants was 54 years (SD: 10), and 74% had
infiltrating ductal carcinoma, 16% had infiltrating lobular
carcinoma and the balance had other or mixed histologi-
cal types. The majority (74%) received less invasive sur-
gery (complete local excision versus mastectomy), had
lymph node dissection (87%) with a median of 12 (range
1-47) nodes examined and 0 (range 0-39) positive nodes.
Radiation was a common adjuvant therapy, received by
approximately 70% of women. Approximately 40%
received chemotherapy and 60% received hormone ther-
apy. Overall, approximately 30%, 48% and 17% of women
received one, two or all of these forms of adjuvant ther-
apy, respectively. With the exception of hormone ther-
apy, active chemotherapy and/or radiation therapy were
completed by nine months PS for 98% of the group.
Upper-body function
Overall, UBF improved throughout the 12-month testing
period, with the majority of improvement occurring
between six- and 12-months PS, irrespective of whether
UBF was measured objectively or via self-report (Table
1). Depending on the UBF measure, up to 42% of
women experienced UBF declines between six- and 18-
months PS (Table 2). These results were insensitive to
classification of declining UBF as either any decline or
decline > 10%; classifications were unchanged for UBSE
Table 1 Mean upper-body function scores between six- and 18-months post-surgery*
Months post-surgery
6 9 12 15 18
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Objective measures
UBSE (kg) 212 0.8 (0.5) 185 0.9‡ (0.6) 179 0.9‡ (0.6) 169 1.0‡ (0.6) 186 0.9‡ (0.6)
HG Strength (kg) 215 16.1 (6.7) 190 16.3 (6.6) 187 16.6 (6.9) 174 17.3‡ (7.1) 187 16.9 (7.5)
Flexibility† (degrees) 215 143.0 (12.5) 191 145.7‡ (11.2) 189 147.5‡ (10.2) 178 148.3‡ (10.4) 195 150.2‡ (10.5)
Self-report measure
DASH score 258 14.2 (14.2) 256 13.0‡ (14.1) 254 11.4‡ (12.6) 248 11.3‡ (13.0) 246 12.0‡ (14.7)
Abbreviations: UBSE, upper-body strength and endurance; HG, hand grip; DASH, Disability of the Arm Shoulder and Hand questionnaire (0-100 scale, lower score
= better function); SD, standard deviation.
* Results presented have been appropriately weighted (< 50 years:1.0; > 50 years:1.3) for oversampling of younger women.
† Flexibility relates to flexion of the shoulder.
‡ Statistically significant difference p < 0.05 from six months post-surgery.
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(data not shown) and similar for DASH (28% instead of
34% were categorised as decliners).
Declines in upper-body function between six- and
18-months post-surgery
Adjusted relationships between personal and treatment
characteristics and odds of decline in UBF between six-
and 18-months PS are presented in Table 3. Older age,
lower socioeconomic status as defined by income, being
treated on the dominant side, having a mastectomy and
more extensive lymph node surgery were associated
with 2- to 3.5-fold increased odds of decline in objective
UBF, with the relationships supported statistically (p <
0.05) except for having a mastectomy and extent of
Table 2 Proportion of women whose upper-body function declined, showed no change or improved between six- and
18-months post-surgery*
Change in upper-body function from six- to 18-months post-surgery
Declined No change = 0 Improved Total
n (%) Median Change
(Min, Max)
n (%) n (%) Median Change
(Min, Max)
n (%)
Objective measures
UBSE (kg) 41 (22.8) -0.5 (-1.0, -0.25) 60 (32.9) 82 (44.3) +0.5 (0.25, 2.5) 183 (100.0)
HG Strength (kg) 76 (41.6) -3.1 (-14.0, -0.5) 10 (5.7) 99 (52.7) +4.0 (0.5, 15.0) 185 (100.0)
Flexibility† (degrees) 35 (17.7) -10.0 (-45.0,-3.0) 39 (20.1) 119 (62.1) +10.0 (5.0, 40.0) 193 (100.0)
Self-reported measures
DASH score 76 (33.8) +4.2 (0.6, 48.3) 22 (9.7) 134 (56.6) -5.0 (-43.3, -0.7) 232 (100.0)
Abbreviations: UBSE, upper-body strength and endurance; HG, hand grip; DASH, Disability of the Arm Shoulder and Hand questionnaire (0-100 scale, lower score
= better function).
* Results have been appropriately weighted (< 50 years:1.0; > 50 years:1.3) for oversampling of younger women.
† Flexibility relates to flexion of the shoulder.
Table 3 Personal and treatment-related characteristics associated with declines in upper-body function between
six- and 18-months post-surgery*
Odds of a Decline in UBSE
Decline n = 41 (22.8%)
Odds of a Decline in DASH
Decline n = 76 (33.8%)
Characteristics† n Bivariate OR Adjusted OR
(95% CI)
p-value n Bivariate
OR
Adjusted OR
(95% CI)
p-value
Age 0.03 0.05
< 50 61 1.00 1.00 ref 80 1.00 1.00 ref
50+ 122 1.48 2.81 (1.14, 6.97) 152 2.35 1.94 (1.01, 3.75)
Income 0.04 0.03
> $52,000 (include miss) 88 1.00 1.00 ref 104 1.00 1.00 ref
$26,000-$51,999 50 0.90 1.76 (0.67, 4.60) 65 1.71 1.90 (0.98, 3.68)
< $26,000 45 1.52 3.31 (1.29, 8.53) 63 2.47 2.46 (1.25, 4.85)
Treated on Dominant Side 0.01 0.01
No 88 1.00 1.00 ref 118 1.00 1.00 ref
Yes 95 2.40 2.56 (1.20, 5.42) 114 1.74 2.15 (1.24, 3.73)
Surgery 0.06
CLE 138 1.00 1.00 ref
Mastectomy 45 1.95 2.25 (0.98, 5.21)
Lymph Nodes Removed 0.35 0.02
None 24 1.00 1.00 ref 33 1.00 1.00 ref
1 to 19 137 3.38 2.93 (0.68, 12.67) 166 2.22 2.63 (1.07, 6.45)
20+ 22 2.77 2.65 (0.43, 16.38) 33 2.69 4.81 (1.64, 14.14)
Lymphoedema 0.21
No 154 1.00 1.00 ref
Yes 18 1.73 2.41 (0.90, 6.44)
Missing 60 1.27 1.15 (0.62, 2.11)
Abbreviations: UBSE, upper-body strength and endurance; DASH, Disability of the Arm, Shoulder and Hand questionnaire (0-100 scale, lower score = better
function); CI, Confidence Interval; ref, referent category against which all others are compared.
* Results have been appropriately weighted (< 50 years:1.0; > 50 years:1.3) for over sampling of younger women and adjusted for baseline upper-body function values.
† All characteristics measured at baseline, six-months post-diagnosis.
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lymph node removal. Lower socioeconomic status, being
treated on the dominant side and more extensive lymph
node removal were also associated with increased odds
of self-reported UBF declines (OR: 2.2-5.4; p < 0.05). In
addition, older age was statistically but not clinically
(OR: 1.9, p = 0.05) associated with increased odds of
self-reported UBF declines, while having lymphoedema
was clinically but not statistically associated with
declines (OR: 2.4, p = 0.21).
Objective and self-reported upper-body function and
quality of life
Cross-sectional analyses using data from six- and 18-
months PS demonstrate that there is a strong, inverse
association between self-reported UBF (lower scores
indicate better function) and QoL (r = -0.7 at each time,
p < 0.01), but weak linear association between objective
UBF and QoL (r = 0.18, p < 0.05 at six-months PS; r =
0.1, p = 0.12 at 18-months PS). Table 4 presents results
of linear regression analyses exploring the relationships
between change in UBF (from six- to 18-months PS)
and QoL at 18-months PS, adjusting for baseline UBF as
well as potential confounders identified elsewhere [24].
Declines in UBF between six- and 18-months PS were
associated with lower QoL at 18-months PS, but the
association was only clinically and statistically significant
for self-reported UBF (greater than 7 unit difference
between decliners and improvers, p < 0.01).
Discussion
Upper-body morbidity is common following treatment
for breast cancer despite advances in treatment methods
that have led to less invasive surgical techniques, such
as sentinel node biopsy, and more refined, targeted
radiation methods. While, on average, UBF improves
between six- and 18-months PS, average change in UBF
obscures substantial variation among individuals. Up to
40% (and no less than 17%) of women experienced
declines in function during the 12-month study period.
That is, even using six months following breast cancer
surgery as baseline (rather than pre-diagnosis measures,
which were unavailable for this study), further declines
in UBF still occurred. Moreover, both objectively and
subjectively measured UBF and declines in UBF have
important implications for reported QoL.
Based on this and earlier work, the inter-relationships
between UBF and QoL are emerging. Our results indi-
cate that the relationships between objectively measured
UBF and QoL post-surgery are minimal. In contrast,
perceived UBF at both baseline and 18 months post-sur-
gery revealed strong associations with QoL at the 18-
month assessment, as was the association between per-
ceived declines in UBF from six to 18 months post-sur-
gery and QoL at 18 months post-surgery. That is, better
perceived function and larger improvements in per-
ceived function were associated with higher QoL. These
findings are important for two reasons. First, we [25]
and others [20] have reported that QoL can predict sur-
vival among women with breast cancer; hence, improv-
ing QoL has multiple benefits. Second, the modest
correlation between objective and perceived UBF
reported elsewhere [15] suggests that any intervention
to improve UBF will need to attend to women’s expecta-
tions as well as their physical function. Figure 1 provides
a conceptual framework that could be tested, and
Table 4 Linear regression analyses of the relationships
between changes in upper-body function (self-reported
and objective) between six- and 18-months post-surgery
and quality of life at 18-months post-surgery*
Quality of life (FACTB+4) at 18-months post-
surgery
n Bivariate
Mean
Adjusted†
Mean (95% CI)
p-value
Objective upper-body function
UBSE change‡ 0.10
declined 40 128.7 123.4 (118.5, 128.2)
no change 60 132.6 127.9 (123.6, 132.2)
improved 78 132.4 129.1 (125.2, 133.0)
Self-reported upper-body function
DASH change‡ < 0.01
declined 75 125.3 121.5 (118.2, 124.9)
no change 22 145.1 127.8 (122.5, 133.2)
improved 133 130.7 130.4 (127.5, 133.3)
Abbreviations: FACTB+4, quality of life as measured by the Functional
Assessment of Cancer Therapy Questionnaire (0 to 160 scale, higher score =
better quality of life); UBSE, upper-body strength and endurance; DASH,
Disability of the Arm, Shoulder and Hand questionnaire (0-100 scale, lower
score = better function); CI, confidence intervals.
* Results presented have been appropriately weighted (< 50 years:1.0; > 50
years:1.3) for over-sampling younger women.
† Means adjusted for all variables in table along with age, marital status, type
of surgery, adjuvant therapy, number of co-morbidities, perceived handling of
stress, baseline quality of life and baseline UBSE and DASH scores [24].
‡ Change scores from six- to 18-months post-surgery, no change defined as 0.
Figure 1 Proposed relationships between upper-body function,
quality of life and survival.
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developed further, in future longitudinal studies invol-
ving a larger breast cancer cohort than ours.
Given the potential clinical significance of UBF follow-
ing breast cancer diagnosis, we sought to identify perso-
nal or behavioural characteristics that increase the
likelihood of declining UBF. Earlier work by our group
explored the relationship between treatment on the
dominant side and UBF, and found that the strength of
the relationship was as strong as that found between
extent of lymph node removal (an established risk fac-
tor) and UBF [15]. Age, presence of co-morbidities and
lower socioeconomic status also have been reported to
influence arm function [15,26].
Older age, lower socioeconomic status, treatment on
the dominant side and/or more extensive surgery to the
chest wall or axilla were each independently associated
with experiencing declines in UBF between six- and 18-
months PS in this study. There also was evidence that
having lymphoedema was associated with declines in
perceived function during this period. The relationship
between UBF declines and treatment on the dominant
side may reflect, at least in part, regression to the mean,
since the dominant side is typically stronger (clinically
and perceived) compared to the non-dominant side. It is
also pertinent to highlight that these characteristics
together explain less than one-third of the variance for
declines in objective UBF and less than 15% of the var-
iance for self-reported function. More work, involving a
more comprehensive assessment of potential risk factors
or improving our assessments of known risk factors, is
required to better understand who is at risk of experien-
cing UBF declines. Nevertheless, these results provide
some initial description of women with breast cancer
who might benefit from targeted intervention, focusing
on UBF.
Conclusion
This was a longitudinal study, using a population-based,
representative sample of women with breast cancer,
with results describing cross-sectional and predictive
relationships between UBF and QoL. It is evident that
declines in UBF continue to occur for some women well
beyond the treatment period and that optimal UBF in
the short- and longer-term following breast cancer is
important with respect to concurrent QoL and subse-
quent QoL. Consequently, these findings provide
support for the integration of a rehabilitation program
into the care of women with breast cancer, which not
only targets minimising declines and facilitating recovery
during and following breast cancer treatment, but also
assists women to optimise clinical function and come to
terms with perceived changes that have occurred with
respect to UBF. Given the extensive physical and psy-
chosocial benefits that are known to occur with physical
activity during and following breast cancer treatment
[27], it seems plausible that a rehabilitation program
with an emphasis on helping women become and/or
stay active throughout their breast cancer experience
would assist in this regard.
Abbreviations
CI: confidence interval; DASH: Disability of the Arm Shoulder and Hand
questionnaire; FACT-B+4: Functional Assessment of Cancer Therapy-Breast;
HGS: hand grip strength; OR: odds ratio; PS: post-surgery; QoL: quality of life;
SD: standard deviation; UBF: upper-body function; UBSE: upper-body
strength and endurance.
Acknowledgements
The contributions of the women who participated in the study, who made
this work possible, are also gratefully acknowledged. This work was
supported by a research project grant as well as a research fellowship, both
from the National Breast Cancer Foundation, Australia. The authors had full
responsibility for the study design, analysis, and interpretation of the data;
the decision to submit the manuscript for publication; and the writing of
the manuscript.
Author details
1School of Public Health, Queensland University of Technology, Victoria Park
Road, Kelvin Grove, Queensland, 4059, Australia. 2Institute of Health and
Biomedical Innovation, Queensland University of Technology, Victoria Park
Road, Kelvin Grove, Queensland, 4059, Australia.
Authors’ contributions
SCH supervised data collection and contributed to analysis, data
interpretation and manuscript writing. SR and TD carried out analysis and
contributed to manuscript writing. DB and BN provided critical input in data
interpretation and manuscript writing. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 20 April 2010 Accepted: 31 August 2010
Published: 31 August 2010
References
1. Australian Institute of Health and Welfare and National Breast Cancer
Centre: Breast cancer in Australia: an overview. Canberra 2006.
2. Satariano W, Ragland D, DeLorenze GN: Limitations in upper-body
strength associated with breast cancer: A comparison of black and
white women. J Clin Epidemiol 1996, 49:535-544.
3. Hladiuk M, Huchcroft S, Temple W, Schnurr BE: Arm function after axillary
dissection for breast cancer: A pilot study to provide parameter
estimates. J Surg Oncol 1992, 50:47-52.
4. Keramopoulos A, Tsionou C, Minaretzis D, Michalas S: Arm morbidity
following treatment of breast cancer with total axillary dissection: A
multivariated approach. Oncology 1993, 50:445-449.
5. Lilijegren G, Holmberg L, Uppsala Orebro Breast Cancer Study Group: Arm
morbidity after section resection and axillary dissection with or without
postoperative radiotherapy in breast cancer stage I. Results from a
randomised trial. Eur J Cancer 1997, 33:193-199.
6. Rietman JS, Kijkstra PU, Geertzen JHB, Baas P, de Vries J, Dolsma WV,
Groothoff JW, Eisma WH, Hoekstra HJ: Treatment-related upper limb
morbidity 1 year after sentinel lymph node biopsy or axillary lymph
node dissection for stage I or II breast cancer. Ann Surg Oncol 2004,
11:1018-1024.
7. Schrenk P, Rieger R, Shamiyeh A, Wayand W: Morbidity following sentinel
lymph node biopsy versus axillary lymph node dissection for patients
with breast carcinoma. Cancer 2000, 88:608-614.
8. Gosselink R, Rouffaer L, Vanhelden P, Piot W, Troosters T, Christiaens M:
Recovery of upper limb function after axillary dissection. J Surg Oncol
2003, 83:204-211.
Hayes et al. Health and Quality of Life Outcomes 2010, 8:92
http://www.hqlo.com/content/8/1/92
Page 6 of 7
9. Haid A, Koberle-Wuhrer R, Knauer M, Fritzsche H, Peschina W, Jasarevic Z,
Ammann M, Hergan K, Sturn H, Zimmerman G: Morbidity of breast cancer
patients following complete axillar dissection or sentinel node biopsy
only: a comparative evaluation. Breast Cancer Res Treat 2002, 73:31-36.
10. Leidenius M, Leppanen E, Krogerus L, Von Smitten K: Motion restriction
and axillary web syndrom after sentinel node biopsy and axillary
clearance in breast cancer. Am J Surg 2003, 185:127-130.
11. Peintinger F, Reitsamer R, Stranzi H, Ralph G: Comparison of quality of life
and arm complaints after axillary lymph node dissection vs sentinel
lymph node biopsy in breast cancer patients. Br J Cancer 2003,
89:648-652.
12. Rietman JS, Dijkstra PU, Debreczeni R, Geertzen JHB, Robinson DPH, de
Vries J: Impairments, disabilities and health related quality of life after
treatment for breast cancer: a follow-up study 2.7 years after surgery.
Disabil Rehabil 2004, 26:78-84.
13. Ernst MF, Voogd AC, Balder W, Klinkenbijl JHG, Roukema JA: Early and late
morbidity associated with axillary levels I-III dissection in breast cancer. J
Surg Oncol 2002, 79:151-155.
14. Kuehn T, Klauss W, Darsow M, Regele S, Flock F, Maiterth S, Dahlbender R,
Wendt I, Kreienberg R: Long-term morbidity following axillary dissection
in breast cancer patients - clinical assessment, significance for quality of
life and the impact of demographic, oncologic and therapeutic factors.
Breast Cancer Res Treat 2000, 64:275-286.
15. Hayes S, Battistutta D, Newman B: Objective and subjective upper-body
function six months following diagnosis of breast cancer. Breast Cancer
Res Treat 2005, 94:1-10.
16. Rietman JS, Kijkstra PU, Hoekstra HJ, Eisma WH, Szabo BG, Groothoff JW,
Geertzen JHB: Late morbidity after treatment of breast cancer in relation
to daily activities and quality of life: a systematic review. Eur J Surg Oncol
2003, 29:229-238.
17. Karki A, Simonen R, Malkia E, Selfe J: Impairments, activity limitations and
participation restrictions 6 and 12 months after breast cancer operation.
J Rehabil Med 2005, 37:180-188.
18. Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA: Chronic
arm morbidity after curative breast cancer treatment: prevalence and
impact on quality of life. J Clin Oncol 2002, 20:4242-4248.
19. Engel J, Kerr J, Schlesigner-Raab A, Eckel R, Sauer H, Holzel D: Predictors of
quality of life of breast cancer patients. Acta Oncol 2003, 42:710-718.
20. Gotay CC, Kawamoto CT, Bottomley A, Efficace F: The prognostic
significance of patient-reported outcomes in cancer clinical trials. J Clin
Oncol 2008, 26:1355-1363.
21. Hayes SC, Janda M, Cornish B, Battistutta D, Newman B: Lymphoedema
following breast cancer: incidence, risk factors and effect on upper body
function. J Clin Oncol 2008, 26:3536-3542.
22. Solway S, Beaton D, McConnell S, Bombardier C: The DASH Outcome
Measure User’s Manual, Second Edition Toronto: Institute for Work and
Health, 2 2002.
23. Brady M, Cella D, Mo F, Bonomi A, Tulsky D, Lloyd S, Deasy S, Cobleight M,
Shiomoto G: Reliability and validity of the Functional Assessment of
Cancer Therapy - Breast (FACT-B) quality of life instrument. J Clin Oncol
1997, 15:974-986.
24. Di Sipio T, Hayes S, Janda M, Newman B: What determines the health-
related quality of life among regional and rural breast cancer survivors.
Aust N Z J Public Health 2009, 33(6):534-539.
25. Di Sipio T, Hayes S, Battistutta D, Janda M, Newman B: Patterns, correlates,
and prognostic significance of quality of life following breast cancer.
Psycho-Oncology .
26. Ververs JM, Roumen RM, Vingerhoets AJ, Vreugdenhil G, Coebergh JWW,
Crommelin MA, Luiten EJT, Repelaer van Driel OJ, Schijven M, Wissing JC,
Voogd AC: Risk, severity and predictors of physical and psychological
morbidity after axillary lymph node dissection for breast cancer. Eur J
Cancer 2001, 37:991-999.
27. Hayes S, Spence R, Galvao D, Newton R: Australian Association for
Exercise and Sport Science Position Stand: Optimising cancer outcomes
through exercise. J Sci Med Sport 2009, 12:428-434.
doi:10.1186/1477-7525-8-92
Cite this article as: Hayes et al.: Upper-body morbidity following breast
cancer treatment is common, may persist longer-term and adversely
influences quality of life. Health and Quality of Life Outcomes 2010 8:92.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hayes et al. Health and Quality of Life Outcomes 2010, 8:92
http://www.hqlo.com/content/8/1/92
Page 7 of 7
